HUTCHMED (China) Limited

HUTCHMED (China) Limited is a biopharmaceutical company engaged in the research, development, and commercialization of innovative targeted therapies and immunotherapies. Its focus lies in treating cancer and immunological disorders, serving patients both in Hong Kong and globally. The company's operations are divided into Oncology/Immunology and Other Ventures. Among its key assets is Savolitinib, an inhibitor primarily aimed at non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Another significant compound, Fruquintinib, targets a range of solid tumors, including CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and other gastrointestinal malignancies. Its extensive pipeline also includes Surufatinib, an inhibitor used in various neuroendocrine tumors (NETs), such as pancreatic and non-pancreatic forms, as well as in biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and additional solid tumors. Further therapeutic candidates include HMPL-523, a spleen tyrosine kinase inhibitor developed for hematological cancers and specific chronic immune conditions, and HMPL-689, which targets isoform PI3Kd. The company is also advancing Tazemetostat, an EZH2 inhibitor currently indicated for certain epithelioid sarcoma and follicular lymphoma patients. Other investigational compounds in its portfolio encompass HMPL-306 for hematological malignancies, gliomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma; HMPL-295 for various solid tumors; and HMPL-653, designed to treat metastatic solid tumors and tenosynovial giant cell tumors. Additionally, it is developing Epitinib (HMPL-813) and Theliatinib (HMPL-309), both representing further inhibitor therapies. HUTCHMED frequently partners with leading pharmaceutical and biotechnology firms, holding collaboration agreements with entities such as AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. Established in 2000, the company rebranded from Hutchison China MediTech Limited to HUTCHMED (China) Limited in May 2021. Its corporate headquarters are situated in Central, Hong Kong.

HUTCHMED (China) Limited trades as HCM.L on LSE. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in GBP.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows £548.65M of revenue and £457.02M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

HUTCHMED (China) Limited can be compared against peers such as Allergy Therapeutics plc, Animalcare Group plc, Beximco Pharmaceuticals Limited, Chill Brands Group PLC, ECO Animal Health Group plc, Genus plc.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of £1.47B, beta of 0.37, and return on equity of +37.0%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

HCM.L currently shows total debt of £97.76M and beta of 0.37. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.hutch-med.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.